Compare SNDA & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDA | URGN |
|---|---|---|
| Founded | 1990 | 2004 |
| Country | United States | United States |
| Employees | N/A | 291 |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 1997 | 2016 |
| Metric | SNDA | URGN |
|---|---|---|
| Price | $36.92 | $28.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $35.75 | $29.29 |
| AVG Volume (30 Days) | 617.1K | ★ 829.4K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $381,141,000.00 | $1,128,000.00 |
| Revenue This Year | $68.73 | $129.09 |
| Revenue Next Year | $11.11 | $70.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.24 | N/A |
| 52 Week Low | $23.66 | $3.61 |
| 52 Week High | $39.66 | $32.37 |
| Indicator | SNDA | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.75 | 59.44 |
| Support Level | $30.78 | $17.86 |
| Resistance Level | $38.74 | $30.00 |
| Average True Range (ATR) | 1.93 | 2.04 |
| MACD | -0.19 | -0.08 |
| Stochastic Oscillator | 58.23 | 62.90 |
Sonida Senior Living Inc is an owner-operator of senior housing communities in the United States in terms of resident capacity. It provides senior living services to the elderly, including independent living, assisted living, Respite Care and Temporary Care Programs, Home Care Services, and memory care services. The company's objective is to provide value to residents by providing quality senior housing services at reasonable prices. The basic services offered by the company at its senior housing communities comprise meals, housekeeping, laundry, 24-hour staffing, transportation, social and recreational activities, and healthcare monitoring.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.